Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-47S5
Application #
8709078
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2014-12-31
Budget Start
2012-01-09
Budget End
2014-12-31
Support Year
47
Fiscal Year
2013
Total Cost
$18,456
Indirect Cost
$8,017
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Salo-Mullen, Erin E; Lynn, Patricio B; Wang, Lu et al. (2018) Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Fam Cancer 17:71-77
Sigel, Carlie S; Krauss Silva, Vitor Werneck; Reid, Michelle D et al. (2018) Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol 126:44-53
Sauter, Craig S; Matasar, Matthew J; Schoder, Heiko et al. (2018) A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 131:1805-1808
Berry, Sean L; Tierney, Kevin P; Elguindi, Sharif et al. (2018) Five years' experience with a customized electronic checklist for radiation therapy planning quality assurance in a multicampus institution. Pract Radiat Oncol 8:279-286
Breitbart, William (2018) Jimmie C. Holland, M.D. Psychosomatics 59:123-124
Geller, Shamir; Pitter, Ken; Moskowitz, Alison et al. (2018) Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clin Lymphoma Myeloma Leuk 18:e279-e281
Romesser, Paul B; Pei, Xin; Shi, Weiji et al. (2018) Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys 100:59-67
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Scott, Jessica M; Nilsen, Tormod S; Gupta, Dipti et al. (2018) Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation 137:1176-1191
Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91-97

Showing the most recent 10 out of 8799 publications